LAURUSLABS Stock Overview
Engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Laurus Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹434.90 |
| 52 Week High | ₹471.00 |
| 52 Week Low | ₹328.15 |
| Beta | 1.13 |
| 1 Month Change | -1.77% |
| 3 Month Change | 8.48% |
| 1 Year Change | 18.20% |
| 3 Year Change | -26.73% |
| 5 Year Change | 555.46% |
| Change since IPO | 352.64% |
Recent News & Updates
Recent updates
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.40
Apr 28
Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jan 27Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 01Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year
Oct 22These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well
Jul 06Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20
Apr 30Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 18Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 27Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?
Sep 09Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet
Jun 11Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year
May 02Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Feb 26With EPS Growth And More, Laurus Labs (NSE:LAURUSLABS) Is Interesting
Feb 11Does Laurus Labs (NSE:LAURUSLABS) Have A Healthy Balance Sheet?
Nov 26Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.80
Nov 13I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease
Nov 12Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80
Oct 30A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)
Oct 05Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
Aug 10Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Jul 23Is Laurus Labs Limited (NSE:LAURUSLABS) Worth ₹547 Based On Its Intrinsic Value?
Jun 06We Think That There Are Issues Underlying Laurus Labs' (NSE:LAURUSLABS) Earnings
May 06Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
May 05We Think Laurus Labs (NSE:LAURUSLABS) Can Stay On Top Of Its Debt
Mar 16Could The Laurus Labs Limited (NSE:LAURUSLABS) Ownership Structure Tell Us Something Useful?
Mar 01Shareholders Are Raving About How The Laurus Labs (NSE:LAURUSLABS) Share Price Increased 331%
Feb 16Shareholder Returns
| LAURUSLABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.7% | 1.7% | 2.7% |
| 1Y | 18.2% | 53.9% | 44.9% |
Return vs Industry: LAURUSLABS underperformed the Indian Pharmaceuticals industry which returned 53.9% over the past year.
Return vs Market: LAURUSLABS underperformed the Indian Market which returned 44.9% over the past year.
Price Volatility
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: LAURUSLABS has not had significant price volatility in the past 3 months.
Volatility Over Time: LAURUSLABS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,753 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system.
Laurus Labs Limited Fundamentals Summary
| LAURUSLABS fundamental statistics | |
|---|---|
| Market cap | ₹234.48b |
| Earnings (TTM) | ₹1.61b |
| Revenue (TTM) | ₹50.41b |
146.0x
P/E Ratio4.7x
P/S RatioIs LAURUSLABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAURUSLABS income statement (TTM) | |
|---|---|
| Revenue | ₹50.41b |
| Cost of Revenue | ₹24.32b |
| Gross Profit | ₹26.08b |
| Other Expenses | ₹24.48b |
| Earnings | ₹1.61b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.98 |
| Gross Margin | 51.75% |
| Net Profit Margin | 3.19% |
| Debt/Equity Ratio | 60.9% |
How did LAURUSLABS perform over the long term?
See historical performance and comparison